Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Treasury Shares (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Treasury Shares for 10 consecutive years, with $76932.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares fell 33.33% year-over-year to $76932.0, compared with a TTM value of $76932.0 through Dec 2025, down 33.33%, and an annual FY2025 reading of $76932.0, down 33.33% over the prior year.
  • Treasury Shares was $76932.0 for Q4 2025 at Spyre Therapeutics, down from $115398.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $190000.0 in Q4 2021 and bottomed at $5660.0 in Q4 2022.
  • Average Treasury Shares over 5 years is $132919.4, with a median of $151932.5 recorded in 2022.
  • The sharpest move saw Treasury Shares plummeted 97.02% in 2022, then surged 2618.46% in 2023.
  • Year by year, Treasury Shares stood at $190000.0 in 2021, then tumbled by 97.02% to $5660.0 in 2022, then soared by 2618.46% to $153865.0 in 2023, then decreased by 25.0% to $115398.0 in 2024, then tumbled by 33.33% to $76932.0 in 2025.
  • Business Quant data shows Treasury Shares for SYRE at $76932.0 in Q4 2025, $115398.0 in Q4 2024, and $153865.0 in Q4 2023.